Menu

Studies Retracted After UCLA Investigation

Most of the authors have had papers pulled in the past.

Jul 21, 2017
Diana Kwon

PIXABAY, JACKMAC34A 2011 Cancer Research paper was retracted earlier this month (July 2) after an investigation by the University of California, Los Angeles (UCLA). The work was conducted by a group of cancer investigators at the university, including James Economou, the former vice chancellor for research.

According to the retraction report, the request came from UCLA, where an institutional review found that one of the paper’s figures duplicated aspects of another paper.

“This is the second retraction we’re aware of to come out of an investigation by UCLA’s Office of Research Policy and Compliance that has touched this group of scientists,” Retraction Watch reports. A 2012 Molecular Cancer Therapeutics paper coauthored by Economou was retracted in May.

This is the fourth retraction for one of the study’s coauthors, Benjamin Bonavida, a retired UCLA scientist. When asked about the most recent Cancer Research study, he tells Retraction Watch that “all the work was done in Economou’s lab, not mine. I have no idea what exactly took place.”

Only one of the coauthors of the Cancer Research paper has no previous retractions.

Retractions of scientific papers are on the rise. Just last year, more than 650 papers were pulled for various reasons, ranging from image duplication to fraud.

See “Infographic: Web of Retractions

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.